Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Roche 17.5245, Structure Therapeutics 0.
* Roche reports semi-annually. Values are evenly split across both quarters within each half.
Roche vs Structure Therapeutics: Revenue Comparison
Roche (RHHBY) and Structure Therapeutics (GPCR) are peers in GLP-1. Roche reported revenue of $35.0B as of Q2 2026, compared with $0 for Structure Therapeutics. Roche leads on revenue.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Roche, Structure Therapeutics.| Metric | Roche | Structure Therapeutics |
|---|---|---|
| Market Cap | - | - |
| Revenue | $35.05B | $0 |
| Cost of Revenue | $9.21B | $0 |
| Gross Profit | $25.84B | $0 |
| Operating Income | $10.90B | $-119.00M |
| Net Income | $7.93B | $-106.00M |
| R&D Expense | $8.35B | $100.00M |
| Earnings Per Share | $1.23 | -$1.47 |
| Gross Margin | 73.7% | - |
| Operating Margin | 31.1% | - |
| Net Profit Margin | 22.6% | - |
| Free Cash Flow | $6.46B | $-120.00M |
| Cumulative Free Cash Flow | $305.80B | $-589.00M |
| Operating Cash Flow | $8.28B | $-120.00M |
| Cash & Equivalents | $6.13B | $273.00M |